Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 versus AMINOSYN HF 8.
Head-to-head clinical analysis: AMINOSYN 3 5 versus AMINOSYN HF 8.
AMINOSYN 3.5% vs AMINOSYN-HF 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
Aminosyn-HF 8% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue repair in patients unable to tolerate oral intake.
Intravenous administration of 500 mL to 1000 mL per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 mL/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
1-2 g/kg/day intravenously as total parenteral nutrition, typically administered as a continuous infusion over 24 hours.
None Documented
None Documented
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Not applicable as amino acids are rapidly cleared; terminal half-life of infused amino acids is approximately 10-30 minutes.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Renal: >90% as amino acids and metabolites; fecal: <5%.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution